We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for infantile nystagmus (IN). Forms of IN associated with variations in CACNA1F, FRMD7 and GPR143 genes have X-linked recessive inheritance, whereas variations in SLC38A8, TYR and TYRP1 genes have an autosomal recessive inheritance and variations in COL11A1, CRYBA1 and PAX6 genes have an autosomal dominant inheritance. The prevalence of all forms of IN is estimated to be 1 in 5000.
Infantile nystagmus
(other synonyms: genetic nystagmus, congenital nystagmus)
General information about the disease
Infantile nystagmus (IN) is a large heterogeneous group of inherited disorders characterized by involuntary spontaneous oscillation of the eyes, present at birth or manifesting in the first three months of life. It can manifest as an isolated disorder, mainly related to variations in the FRMD7 gene, or as part of more complex syndromes such as albinism, oculocutaneous albinism with TYR and TYRP1 variations, X-linked ocular albinism with GPR143 variations, Chediak Higashi syndrome, achromatopsia, blue cone monochromatism, X-linked congenital stationary night blindness with CACNA1F variations, Stickler syndrome with COL11A1 variations, foveal hypoplasia with SLC38A8 and PAX6 variations, congenital cataract with CRYBA1 variations, Leber congenital amaurosis, Joubert syndrome, Down syndrome, Bardet Biedl syndrome and many others (1) .
The prevalence of all forms of IN is estimated to be 1 in 5000 (2 
Aims of the test
• To determine the gene defect responsible for the pathology;
• To confirm clinical diagnosis of the disease;
• To determine carrier status for the disease, for genes with recessive autosomal/ X-linked inheritance.
Test characteristics Expert centers/ Published guidelines
The test is listed in the Orphanet database and is offered by more than 89 accredited medical genetic laboratories in the EU, and in the GTR database, offered by about 82 accredited medical genetic laboratories in the US. The guidelines for clinical use of the test are described in "Genetics home reference" (ghr.nlm.nih.gov).
Test strategy
A multi-gene NGS panel is used for the detection of nucleotide variations in coding exons and flanking introns in the CAC-NA1F, COL11A1, CRYBA1, FRMD7, GPR143, PAX6, SLC38A8, TYR and TYRP1 genes. Potentially causative variants and regions with low coverage are Sanger-sequenced. MLPA is used for detection of duplications and deletions in the COL11A1, FRMD7, GPR143, TYR and PAX6 genes. Sanger sequencing is also used for family segregation studies.
The tests identify variations in known causative genes in patients suspected to have IN. To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml blood in a sterile tube with 0.5 ml K3EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated. Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results

Positive
Identification of pathogenic variants in CACNA1F, COL11A1,
CRYBA1, FRMD7, GPR143, PAX6, SLC38A8, TYR, and TYRP1 genes confirms the clinical diagnosis and is an indication for family studies.
A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on the loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/ other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Inconclusive
Detection of a variant of unknown or uncertain significance: a new variation and/or without any evident pathogenic significance or with insufficient or significant conflicting evidence to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives in order to assess variant segregation and clarify its contribution. In some cases it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments; • sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions; • variations in other genes not investigated by the present test.
Unexpected
Unexpected results may come out from the test, for example information regarding consanguinity, absence of family correlation or the possibility of developing genetically based diseases.
Risk for progeny
In autosomal dominant transmission, the probability that a carrier transmits the disease variant to his/her children is 50% in any pregnancy, independently of the sex of the conceived.
Autosomal recessive transmission needs that both healthy carrier parents transmit their disease variant to his/her children. In this case, the probability of having an affected boy or girl is therefore 25%.
Recessive X linked inheritance: affected males only transmit the disease variant to their daughters. The probability that a female carrier transmits the pathogenic variant to her offspring is 50% in any pregnancy independently of the sex of the conceived. Females who inherit the pathogenic variant will be carriers and usually unaffected. Males who inherit the pathogenic variant will be affected.
Limits of the test
The test is limited by current scientific knowledge regarding the genes and disease. 
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for the disease; b) the genetic test has diagnostic sensitivity greater than or equal to other published tests.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis yes
Differential diagnosis yes
Access to clinical trial (6) yes
Couple risk assessment yes
